{"id":"NCT01103323","sponsor":"Bayer","briefTitle":"Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy","officialTitle":"A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-04","primaryCompletion":"2011-07","completion":"2014-01","firstPosted":"2010-04-14","resultsPosted":"2012-11-19","lastUpdate":"2015-06-24"},"enrollment":760,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Colorectal Cancer"],"interventions":[{"type":"DRUG","name":"Regorafenib (Stivarga, BAY73-4506)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"OTHER","name":"Best Supportive Care (BSC)","otherNames":[]}],"arms":[{"label":"Regorafenib (Stivarga, BAY73-4506)+BSC","type":"EXPERIMENTAL"},{"label":"Placebo+BSC","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, double-blind, placebo-controlled multi-center phase III study to evaluate efficacy and safety of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed on/after all approved drugs for CRC","primaryOutcome":{"measure":"Overall Survival","timeFrame":"From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis (IA).","effectByArm":[{"arm":"Regorafenib (Stivarga, BAY73-4506)+BSC","deltaMin":196,"sd":null},{"arm":"Placebo+BSC","deltaMin":151,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.005178"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":171,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Czechia","France","Germany","Hungary","Israel","Italy","Japan","Netherlands","Portugal","Spain","Switzerland","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["23177514","22421192","38861286","26184520"],"seeAlso":["http://www.clinicaltrialsregister.eu/"]},"adverseEventsSummary":{"seriousAny":{"events":232,"n":500},"commonTop":["Fatigue","Anorexia","Diarrhea","Hand-foot skin reaction","Weight loss"]}}